Search Results

The European Academy of Allergy and Clinical Immunology, with a membership of over 16,000 from 125 countries, annually orchestrates its congress to unveil the latest research and innovative advancements in allergy and clinical immunology.

Valencia Technologies Corporation (" Valencia " or the “Company”), a privately held company, today announced it has retained PRIA Healthcare to assist in patient access for Valencia’s recently FDA approved proprietary product, eCoin®.

Valencia Technologies Corporation, a privately held company, today announced that it has completed the world’s first commercial implantation of eCoin® in Sarasota, FL.

Astria Therapeutics, Inc. today announced that it will present two posters at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Congress in Valencia, Spain on June 1, 2024.

Valencia Technologies, a privately held company, today announced the expansion of its leadership team with the appointments of Jerry Schloffman as Chief Commercial Officer, Jim Crines as Interim Chief Financial Officer, Arthur Rascon as Senior Vice President of Operations, and Ann Decker as Vice President of Reimbursement.

Valencia Technologies Corporation today announced that the U.S. Food and Drug Administration (FDA) has granted premarket approval (PMA) of its eCoin ® leadless tibial neurostimulator for the treatment of urinary incontinence (UUI), which affects over 60% of patients who suffer from Overactive Bladder (OAB).

Ionis Pharmaceuticals, Inc. announced that it will host a live webcast on Friday, May 31th at 8:00 a.m. Eastern Time to discuss the donidalorsen Phase 3 OASIS-HAE and OASISplus study results that will be presented in three late-breaking oral presentations at the 2024 European Academy of Allergy and Clinical Immunology Annual Meeting in Valencia, Spain.

KalVista Pharmaceuticals, Inc., announced that it presented real-world data from US patient surveys that assessed the experience of HAE patients using injectable on-demand treatments at the European Academy of Allergy and Clinical Immunology Congress 2024 that took place in Valencia, Spain.

BioCryst Pharmaceuticals Inc. announced that new data on oral, once-daily ORLADEYO® for the prophylactic treatment of hereditary angioedema will be presented at the European Academy of Allergy and Clinical Immunology meeting in Valencia, Spain from May 31 to June 3, 2024.

Intellia Therapeutics, Inc. today announced the acceptance of a oral presentation from the Phase 1 portion of the ongoing NTLA-2002 Phase 1/2 study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024, taking place May 31 – June 3 in Valencia, Spain.